External Content

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

A staff from a local disease prevention and control centre points to a paper notice for recall on a sealed package of vials containing the rabies vaccines manufactured by the vaccine maker Changsheng Biotechnology in Huangshan, Anhui province, China July 23, 2018. Picture taken July 23, 2018. REUTERS/Stringer

(reuters_tickers)

BEIJING (Reuters) - China's cabinet investigation group has found that vaccine maker Changsheng Bio-technology broke the law in manufacturing rabies vaccines, the state news agency Xinhua reported on Friday.

The investigation group said the company had systematically falsified production and testing records to avoid regulatory scrutiny, according to Xinhua.

"The company used expired materials to produce some rabies vaccine and falsified the production date," the investigation group found.

"To cover up violations, the company systematically fabricated production and testing records."

China has launched sweeping spot checks on vaccine makers around the country after Changsheng was found to have falsified data and sold ineffective vaccines for children.

China's drug regulator has accused Changsheng of fabricating production and inspection records related to a rabies vaccine regularly given to infants.

President Xi Jinping has ordered all relevant departments to investigate the scandal, which has triggered public outrage in what is the latest case of tainted medical products.

The firm also sold 252,600 doses of ineffective DPT vaccines to inoculate children against diphtheria, whooping cough and tetanus.

(Reporting by Beijing Monitoring Desk; editing by Kevin Liffey and Jason Neely)

Neuer Inhalt

Horizontal Line


Survey Swiss Abroad

Survey: Keyboard and Hand close-up

Dear Swiss Abroad, tell us what you think

Survey Swiss Abroad

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.








Click here to see more newsletters

Reuters